Abstract: An abnormality detection device includes: a creation unit that creates learning data from measurement data of an energy storage device; a storage unit that stores a model learned to output a score corresponding to whether or not abnormal measurement data is included in the measurement data when the measurement data is input using the created learning data; a detection unit that detects an abnormality or a sign of abnormality of the energy storage device based on a score output by inputting the measurement data to the model; and a determination unit that determines electric power distribution using an electric power adjustment function of the energy storage device based on the abnormality or the sign of abnormality.

Abstract: A lithium composite metal compound is a lithium composite metal compound represented by Composition Formula (I), in which in a powder X-ray diffraction measurement using CuK? radiation, when a crystallite diameter representing a diffraction peak in a range of 2?=18.7±1 ? is defined as La and a crystallite diameter representing a diffraction peak in a range of 2?=64.5±1 ? is defined as Lb, a ratio (La/Lb) of La to Lb is La/Lb?1.3.

Abstract: A positive electrode active material for lithium secondary batteries, includes: a lithium composite metal compound containing secondary particles formed by aggregation of primary particles; and a lithium-containing tungsten oxide, in which the lithium-containing tungsten oxide is present at least in interparticle spaces of the primary particles, and in a pore distribution of the positive electrode active material for lithium secondary batteries measured by a mercury intrusion method, a surface area of pores having a pore diameter in a range of 10 nm or more to 200 nm or less is 0.4 m2/g or more and 3.0 m2/g or less.

Abstract: A positive electrode active material for lithium secondary batteries, includes: a lithium composite metal compound containing secondary particles formed by aggregation of primary particles; and a lithium-containing tungsten oxide, in which the lithium-containing tungsten oxide is present at least in interparticle spaces of the primary particles, and in a pore distribution of the positive electrode active material for lithium secondary batteries measured by a mercury intrusion method, a surface area of pores having a pore diameter in a range of 10 nm or more to 200 nm or less is 0.4 m2/g or more and 3.0 m2/g or less.

Abstract: The present invention relates to a positive electrode active material for a lithium secondary battery, comprising a powder of a lithium metal composite oxide represented by formula (1) below: Li[Lix(Ni(1?y?z?w)CoyMnzMw)1?x]O2 (1) (wherein M is one or more elements selected from the group consisting of Fe, Cu, Ti, Mg, Al, W, B, Mo, Nb, Zn, Sn, Zr, Ga and V, ?0.1?x?0.2, 0<y?0.4, 0<z?0.4, 0?w?0.1, 0.25<y+z+w), wherein the powder of lithium metal composite oxide includes primary particles and secondary particles that are aggregates of the primary particles, a BET specific surface area of the positive electrode active material for the lithium secondary battery is 1 m2/g or more and 3 m2/g or less, and an average crushing strength of the secondary particles is 10 MPa or more and 100 MPa or less.

Abstract: A positive electrode active material for a lithium secondary battery contains an active material powder including secondary particles that are aggregates of primary particles into and from which lithium ions are doped and dedoped, includes the secondary particles having voids therein, and satisfies the following Requirements (1) and (2) in pore distribution of the positive electrode active material for a lithium secondary battery measured by a mercury porosimetry method. (1) A positive electrode active material for a lithium secondary battery has a pore peak in a range in which a pore radius is 10 nm or more and 200 nm or less. (2) A positive electrode active material for a lithium secondary battery has three or more inflection points of a cumulative pore volume in a range in which the pore radius is 10 nm or more and 3000 nm or less.

Abstract: A lithium metal composite oxide powder includes primary particles; and secondary particles formed by aggregation of the primary particles, in which the lithium metal composite oxide powder is represented by Composition Formula (1), and the lithium metal composite oxide powder satisfies all of requirements (A), (B), and (C).

Abstract: The present invention aims to provide an immunostimulating agent superior in an immunostimulatory effect, particularly a compound useful as a vaccine adjuvant, a pharmaceutical composition containing the compound, a vaccine containing the compound and an antigen. An immunostimulating agent containing at least one kind of a compound represented by the formula (I): wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract: Compounds represented by the following formula (I); wherein each symbol is as defined in the specification, are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.

Abstract: Provided is a compound represented by the following general formula (I), or a pharmaceutically acceptable salt thereof. This novel compound has a glycogen-synthase activation ability, but activates a receptor PPAR to a low degree and is highly safe. In the formula, Ar is an aromatic carbocyclic ring or a heterocyclic ring; and Ar2 is represented by any one of the following rings and the like.

Abstract: In order to provide a composition for treating, improving, or preventing pain, it has been found out that a metallothionein protein is expressed in a normal peripheral nerve, and that the expression is not observed in a peripheral nerve producing pain. Moreover, it has been found out that administering metallothionein to rats having neuropathic pain suppresses the pain in the rats.

Abstract: Provided is a compound represented by the following general formula (I), or a pharmaceutically acceptable salt thereof. This novel compound has a glycogen-synthase activation ability, but activates a receptor PPAR to a low degree and is highly safe. In the formula, Ar is an aromatic carbocyclic ring or a heterocyclic ring; and Ar2 is represented by any one of the following rings and the like.

Abstract: Compounds represented by the following formula (I); wherein each symbol is as defined in the specification, are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.

Abstract: An object is to provide a novel compound which has a glycogen synthase activation ability, but activates a receptor PPAR to a low degree and is highly safe.

Abstract: Compounds represented by the following formula (I); wherein each symbol is as defined in the specification, are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.

Abstract: An object is to provide a novel compound having a higher MGAT2 inhibitory activity than conventional compounds. A compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof is provided.

Abstract: Compounds represented by the following formula (I), are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.

Abstract: Compounds represented by the following formula (I); wherein each symbol is as defined in the specification, are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.

Abstract: Provided is a compound represented by the following general formula (I), or a pharmaceutically acceptable salt thereof. This novel compound has a glycogen-synthase activation ability, but activates a receptor PPAR to a low degree and is highly safe. In the formula, Ar is an aromatic carbocyclic ring or a heterocyclic ring; and Ar2 is represented by any one of the following rings and the like.

Abstract: Disclosed are: a composition for alleviating ultraviolet irradiation-induced damage, which can be used on a daily based and is stable and safe; and a pharmaceutical preparation, a cosmetic and a food composition, each of which comprises the composition. The composition for alleviating ultraviolet irradiation-induced damage contains one or more compounds selected from the group consisting of D-glutamic acid, L-glutamic acid, D-proline, D-cystine, L-cystine, and derivatives and/or salts of the aforementioned compounds. The composition can be used as an external formulation for the skin, a cosmetic composition, an anti-wrinkle agent, a sunscreen agent, a pharmaceutical composition for treating and/or preventing skin diseases, a food composition, or a pharmaceutical composition for preventing or treating cataract.